The FDA has approved baxdrostat ( Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other…
Med Lett Drugs Ther. 2026 Jul 6; 68(1758):105-6 doi:10.58347/tml.2026.1758a
The FDA has approved baxdrostat ( Baxfendy – AstraZeneca), an oral aldosterone synthase inhibitor, for add-on treatment of hypertension in adults whose blood pressure is not adequately controlled on other drugs. Baxdrostat is the first aldosterone synthase inhibitor to become available in the US.
The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics),…
Med Lett Drugs Ther. 2025 Sep 15; 67(1737):152 doi:10.58347/tml.2025.1737e
The FDA has removed the Risk Evaluation and Mitigation Strategy (REMS) requirement for the endothelin receptor antagonists ambrisentan ( Letairis , and generics), bosentan ( Tracleer , and generics), macitentan ( Opsumit , and generics; Opsynvi) , and aprocitentan (Tryvio) , and the endothelin receptor antagonist and angiotensin II receptor antagonist sparsentan (Filspari) that was initially implemented because of a possible risk of embryofetal toxicity.
The FDA has approved the dual endothelin receptor antagonist aprocitentan ( Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure is…
Med Lett Drugs Ther. 2024 Jun 10; 66(1704):92-3 doi:10.58347/tml.2024.1704b
The FDA has approved the dual endothelin receptor antagonist aprocitentan ( Tryvio – Idorsia) for use in combination with other antihypertensive drugs to treat hypertension in adults whose blood pressure is not adequately controlled on other drugs. Three other dual endothelin receptor antagonists, ambrisentan ( Volibris , and generics), bosentan ( Tracleer , and generics), and macitentan (Opsumit) , are available in the US for treatment of pulmonary arterial hypertension.
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed…
Med Lett Drugs Ther. 2024 May 27; 66(1703):81-8 doi:10.58347/tml.2024.1703a
American College of Cardiology/American Heart Association (ACC/AHA) guidelines for treatment of hypertension were last published in 2018. Treatment of hypertensive urgencies and emergencies is not discussed here.